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Abstract
Background: The chemotherapy used to treat lung cancer causes febrile neutropenia in 10 to 40% of patients.
Although most episodes are of undetermined origin, an infectious etiology can be suspected in 30% of cases. In
view of the scarcity of data on lung cancer patients with febrile neutropenia, we performed a retrospective study
of the microbiological characteristics of cases recorded in three medical centers in the Picardy region of northern
France.
Methods: We analyzed the medical records of lung cancer patients with neutropenia (neutrophil count < 500/mm
3)
and fever (temperature > 38.3°C).
Results: The study included 87 lung cancer patients with febrile neutropenia (mean age: 64.2). Two thirds of the
patients had metastases and half had poor performance status. Thirty-three of the 87 cases were microbiologically
documented. Gram-negative bacteria (mainly enterobacteriaceae from the urinary and digestive tracts) were
identified in 59% of these cases. Staphylococcus species (mainly S. aureus) accounted for a high proportion of the
identified Gram-positive bacteria. Bacteremia accounted for 60% of the microbiologically documented cases of
fever. 23% of the blood cultures were positive. 14% of the infections were probably hospital-acquired and 14%
were caused by multidrug-resistant strains. The overall mortality rate at day 30 was 33% and the infection-related
mortality rate was 16.1%. Treatment with antibiotics was successful in 82.8% of cases. In a multivariate analysis,
predictive factors for treatment failure were age >60 and thrombocytopenia < 20000/mm
3.
Conclusion: Gram-negative species were the most frequently identified bacteria in lung cancer patients with
febrile neutropenia. Despite the success of antibiotic treatment and a low-risk neutropenic patient group, mortality
is high in this particular population.
Background
Lung cancer is the most frequent and severe cancer in
France. In 2000, the incidence was 52.2 per 100,000
inhabitants per year [1]. Although lung cancer mainly
affects male, middle-aged smokers, the recent increase
in the number of female smokers is changing these data
[2]. The choice of treatment depends on the lung can-
cer’s histological characteristics. When chemotherapy is
used, neutropenia (i.e. a neutrophil count < 500/mm
3)
of variable severity and duration occurs in 10 to 40% of
patients (depending on the type of chemotherapy) [3,4].
In solid tumors, neutropenia usually lasts for less than 7
days. However, the condition can be complicated by
fever (a body temperature of over 38.3°C once an hour
or over 38°C twice an hour) in 8 to 15% of cases and is
thus referred to as febrile neutropenia [5,6]. Microbiolo-
gical evidence is found in only 30% of patients with neu-
tropenic fever. Indeed, approximately 60% of patients
with febrile neutropenia have neither clinical signs nor
microbiological evidence of infection [7].
Prior to the 1980s, neutropenic fever was due to
Gram-negative bacteria (e.g. Escherichia coli, Klebsiella
sp, Pseudomonas aeruginosa, etc.) in 70% of cases [8,9].
Since then, the proportion of Gram-positive bacteria has
risen, with Staphylococcus epidermidis being found more
frequently than Staphylococcus aureus [10].
Lung cancer patients are characterized by the frequent
presence of Pseudomonas aeruginosa in chronic obstructive
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ities, aggressive tumors and rapid clinical degradation.
Markman and Abeloff (1983) studied the infectious
complications of chemotherapy (with cyclophosphamide,
doxorubicin and etoposide) in 71 patients with small-
cell carcinoma [11]. Although 90% of cases were compli-
cated by febrile neutropenia, an etiology was determined
in only 20% of the latter. The following bacteria were
found: Escherichia coli (n = 3), Streptococcus viridans (n
=2 ) ,Pseudomonas aeruginosa (n = 2), Bacillus sp. (n =
2), Staphylococcus aureus (n = 1), Candida sp. (n = 1),
Enterococcus sp. (n = 1) and one anaerobic Gram-nega-
tive bacillus. None of these cases of febrile neutropenia
resulted in death.
Two other studies in lung cancer patients examined
the outcomes of antibiotic therapy rather than the
microbiological characteristics of the condition [12,13].
No statistically significant differences were found.
Here, we performed a retrospective, descriptive, multi-
center study of the microbiological characteristics of
febrile neutropenia in lung cancer patients hospitalized
in three medical centers in the Picardy region of north-
ern France. The study’s primary objective was to deter-
mine risk factors for antibiotic treatment failure.
Methods
We included adult lung cancer patients (i.e. aged 18 or
over) having undergone chemotherapy (of whatever
type) between January 2000 and July 2006 in three med-
ical centers in the Picardy region. Patients had to have
displayed concomitant neutropenia (i.e. a neutrophil
count < 500/mm
3) and fever (a body temperature >
38.3°C once an hour or over 38°C twice an hour).
Access to the patients’ medical records was provided by
the medical centers’ health informatics departments.
We excluded patients who had already experienced an
episode of febrile neutropenia prior to study entry,
patients with cancers other than lung cancer, cases of
fever without neutropenia, cases of neutropenia without
fever and cases of fever with a clearly non-infectious
etiology.
Data was recorded in a pre-determined questionnaire.
Febrile episodes were classified according to Hughes’ cri-
teria as being microbiologically documented, clinically
documented or of undetermined origin. The success of
antibiotic therapy was defined according to Kern’sc r i -
teria: no fever for 3 successive days, the absence of clini-
cal signs or the eradication of an identified pathogen.
The death of a patient meeting these criteria was not
considered to be a treatment failure [14]. The last criter-
ion for success was the lack of recurrence within 7 days
of the end of antibiotic therapy. We calculated the “first-
line antibiotic treatment failure rate” (i.e. failure of the
first-line antibiotic prescribed) and the “overall antibiotic
treatment success rate” (i.e. a successful outcome when
one or more antibiotics had been prescribed).
We also recorded the presence of the following sever-
ity criteria on admission: systolic blood pressure < 90
mmHg, blood oxygen partial pressure < 60 mmHg, dis-
seminated intravascular coagulation, confusion, cardiac
failure, blood transfusion for hemorrhage, kidney failure
and admission to the intensive care unit [15].
Data were gathered in compliance with the principles
of the Declaration of Helsinki and then anonymized. No
patient consent was needed because of the confidential
nature of this study, which was approved by the inde-
pendent ethics committee at Saint-Quentin Medical
Center.
Statistical analysis was performed with Excel
® 2000
(Microsoft EMEA, Courtaboeuf, France) and SPSS (SPSS
Inc., Chicago, IL) software. Quantitative variables were
expressed as the mean ± standard deviation and qualita-
tive variables were expressed as the frequency and per-
centage. Univariate, comparative analyses were
performed by using Fisher’s exact test (for qualitative
variables) and the Mann-Whitney test (for quantitative
variables). The threshold for statistical significance was
set to p < 0.05. Multivariate analyses were performed by
using logistic regression.
Results
Over the study period, 646 patients were treated for
lung cancer. Ninety-three of these patients (14%) ful-
filled the inclusion criteria (i.e. hospitalized for febrile
neutropenia) and 6 were excluded (2 cases of fever with
a non-infectious etiology, 3 patients with incomplete
data and 1 patient enrolled twice). Details are shown in
Figure 1 and 87 episodes were analyzed. The study
population (mean age: 64.2 ± 9.6) was generally com-
prised of male (male/female ratio: 8:1) smokers (95%, n
= 83). Chronic obstructive pulmonary disease was
recorded in 53.5% of cases (n = 46) (for details, see
Table 1). Half of these patients had poor performance
status and 14% had been hospitalized prior to the epi-
sode of febrile neutropenia.
Almost two thirds of the patients had metastatic can-
cer when they were diagnosed with febrile neutropenia
(62% in all, including brain metastases in 14% and
metastases at more than two sites in 20%). Thirty-one
percent of the non-metastatic patients were non-oper-
able and 28.7% (n = 25) of patients had also been trea-
ted with radiotherapy (data not shown). Eighty patients
(92%) had an implantable venous access system and 15
patients (17%) had undergone two or more cycles of
chemotherapy.
Thirteen percent of the patients had febrile neutrope-
nia (87 out of 646). Sixteen events were excluded
because they did not correspond to the patient’sf i r s t
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tion of neutropenia was 4.4 ± 2.4 days (range: 1-11) and
10% of the episodes lasted more than 8 days.
The fever was classified as being of undetermined ori-
gin in 46% of cases (n = 40), clinically documented in
45% of cases (n = 39) (including 14 (16%) with no
microbiology documentation) and microbiologically
documented in 38% of cases (n = 33). Three quarters of
the microbiologically documented cases (n = 25 out of
33) were also clinically documented. The clinically docu-
mented infections were classified as follows: 21 lower
respiratory tract infections (53%), 9 digestive infections
(23%), 3 catheter infections (8%), 3 skin infections (8%),
2 urinary tract infections and one upper respiratory
tract infection.
Of the 33 patients with identified pathogens, 7 (21.2%)
had two different bacterial infections and one had 3.
Most of the identified germs were Gram-negative bac-
teria (n = 24; 59%) and most of the latter were Entero-
bacteriaceae (especially Escherichia coli) (n = 11 out of
16). Most of the Gram-positive bacteria (n = 17) were
Staphylococcus sp. (above all S. aureus;n=6o u to f9 ) .
Details are shown in Table 2. Neither Gram-positive
cocci nor Gram-negative bacilli were associated with
mortality (p = 0.43 and p = 1, respectively). However,
infection with Gram-negative bacilli was significantly
associated with first-line antibiotic treatment failure in
cases of microbiologically documented fever (9 out of 21
successes vs. 10 out of 12 failures; p = 0.02).
Gram-negative bacilli predominated in both monomi-
crobial and polymicrobial infections. There were 13
Gram-negative monomicrobial infections and 11 Gram-
positive monomicrobial infections. One diagnosis was
646 patients treated for 
lung cancer 
191 patients with white 
blood cell count 
93 patients with 
neutropenia and fever 
87 patients included 
2 non infectious fevers 
3 incomplete data 
1 redundancy  
Figure 1 Flow charts.
Table 1 Characteristics of patients
Number (%) or means ±S D
Sex (M/F) 78/9
Age (year) 64.2 ± 9.6
Score WHO ≥ 2 54/86 (62.8)
Allergy (penicillin) 2/87 (2.3)
Comorbidity 53/87 (61)
- diabetes 17 (19.5)
- therapy by corticosteroids 24 (27.6)
- immunosuppression 2 (2.3)
- undernutrition 5 (5.7)
- other cancer 10 (11.5)
- other comorbidity 10 (11.5)
No of comorbidities 1.3 ± 0.5
No. of comorbidities ≥ 2 11/87 (12.6)
Smoking 83/87 (95.4)
No of packets × No of year of smoking 46.5 ± 19.5
History of pulmonary diseases 58/86 (67.4)
- asbestos 9 (10.5)
- asthma 1 (1.2)
- COPD 46 (53.5)
- restrictive syndrome 7 (8.1)
- bronchiectasis 2 (2.3)
- oxygenotherapy 2 (2.3)
- pulmonary tuberculosis 2 (2.3)
State COPD 39/86
- Normal 2 (2.3)
- FEV1 > 80% of theory 10 (11.6)
- FEV1 between 50 and 80% theory 17 (21)
- FEV1 between 30 and 50% theory 5 (7)
- FEV1 < 30% of theory 3 (3.5)
COPD = Chronic Obstructive Pulmonary Disease, FEV1 = Forced Expiratory
Volume in first second, No = number.
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cellular bacterium, Chlamydia pneumoniae.I np o l y m i -
crobial infections, combinations of several different
Gram-negative bacteria were found in 4 cases. Combina-
tions of several different Gram-positive species and
combinations of Gram-negative and Gram-positive spe-
cies were found in 2 cases each. However, we decided
not to include four other doubtful combinations in
which one of the bacteria was non-pathogenic and was
not isolated from the same body site as the identified
pathogenic species.
Multidrug-resistant bacteria (i.e. those resistant to two
or more antibiotic families, including beta-lactams) were
identified in 6 of the 41 infections (14.6%). Six of the 33
patients (18%) were infected with multidrug resistant
bacteria. All S. pneumoniae were penicillin non-suscepti-
ble (n = 2) and almost half of all Staphylococcus sp. were
methicillin-resistant (n = 4 out of 9). One of the two
Pseudomonas aeruginosa isolates was ceftazidime-resis-
tant and the only Sphingomonas paucimobilis isolate
was found to be multidrug-resistant. There were no van-
comycin-resistant Enterococcus isolates and no gentamy-
cin-intermediate-susceptible S. aureus isolates.
According to the antibiotic susceptibility profile, 24% of
patients (n = 8) would have needed glycopeptides or
cephaloridine.
The isolates were mainly urinary and digestive tract
germs (46%, n = 19), followed by cutaneous (22%, n =
9) and respiratory (20%, n = 8) germs (for details, see
Table 3). Blood cultures were the most frequently posi-
tive samples (23%; 20 positive blood cultures out of 81
samples) and yielded 24 of the 45 germs (including 9 E.
coli,4S. aureus and 4 Streptococcus sp isolates), since 4
patients had polymicrobial bacteremia. The origin of the
bacteremia could be identified in half the cases, since 13
of the 20 cases of bacteremia were associated with clini-
cal signs. The other samples collected for bacteriological
testing were sputum (n = 9), urine (n = 3), stools (n =
4), skin (n = 5) and others (n = 5). A positive blood cul-
ture was not a risk factor for mortality (p = 0.8).
All three centers applied the same antibiotic treatment
guidelines. The first-line treatment was either amoxicil-
lin/clavulanic acid or a combination of cephalosporin
and ciprofloxacin. The concordance between the guide-
lines and actual prescriptions was 65%; the discordances
consisted of adjunction of an aminoglycoside in 41% of
cases and use of a glycopeptide in 6% of cases. The out-
come was favorable in most cases; the overall antibiotic
therapy success rate was 82.8%. The first-line treatment
was effective in 72.4% of cases (63 out of 87) but fell to
63.6% (n = 21 out of 33) in microbiologically documen-
ted episodes. Furthermore, the outcome of first-line
treatment was in line with the in vitro susceptibility
results in 84.8% of cases (28 out of 33). The median
time interval between treatment initiation and apyrexia
was 2 days (range: 1-12).
The mortality rate was 15% at day 7 and 33% at day
30, whereas the infection-related mortality rate was
16.1%. Ten of the 14 deceased patients (71%) had at
least one severity criterion on admission.
In a univariate analysis, the predictive factors for first-
line antibiotic treatment failure were as follows: age>60,
WHO score >2, thrombocytopenia below 20,000/mm
3,
undetermined origin, mismatch between microbiological
results and antibiotic treatment and, lastly, hospital-
acquired infections. The latter three factors did not have
Table 2 Microbiological characteristics of bacteria strains
Classification n (%) Details n
Gram-positive bacteria:1 7
(41%)
Staphylococcus sp: 9
S. epidermidis: 3 (methi-S: 1 - methi-R:
2)
- Gram positive Cocci: 16 S. aureus: 6 (methi-S: 4 - methi-R: 2)
Streptococcus sp: 4
- Streptococcus A :2
- Streptococcus D bovis :1
- Lactococcus lactis cremoris :1
S. pneumoniae:2
Enterococcus sp: 1
- Gram positive Bacilli: 1 Turicella otitidis:1
Gram-negative bacteria:2 4
(59%)
H. influenzae and parainfluenzae:3
Enterobacteriaceae: 16
- Gram negative Bacilli: 23 - E. coli:1 1
- Proteus mirabilis:1
- Klebsiella oxytoca:2
- Salmonella enterica:1
- Citrobacter koseri:1
Pseudomonas aeruginosa:2
Sphingomonas paucimobilis:1
Acinetobacter baumannii:1
- Gram negative Cocci: 1 Moraxella catarrhalis:1
methi-S = methicillin sensitive; methi-R = methicillin resistant; sp = species.
Table 3 Repartition of germ according to their tropism
Uro-digestives germs: 19 strains Enterococcus spp: 1
Enterobacteriaceae: 16
Acinetobacter baumannii :1
Streptococcus bovis :1
Cutaneous germs: 9 strains Coagulase Negative Staphylococcus:3
Staphylococcus aureus:6
Respiratory germs: 8 strains S. pneumoniae:2
Haemophilus influenzae :3
Pseudomonas aeruginosa:2
Moraxella catarrhalis :1
Other: 5 strains Other Streptococcus:3
Sphingomonas paucimobilis :1
Turicella otitidis :1
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treatment (Table 4).
A multivariate analysis revealed that three factors were
predictive of first-line antibiotic treatment failure:
age>60 (p = 0.011), thrombocytopenia <20,000/mm
3 (p
< 0.01) and WHO score >2 (p = 0.012). The first two
factors were also correlated with the overall failure of
antibiotic treatment.
Discussion
As expected, our population was typical of hospitalized
lung cancer patients and primarily comprised elderly
male smokers in poor general health (WHO score >2).
The recent increase in the number of female smokers in
France did not appear to have impacted on the present
study. Likewise, the patients’ prognoses were very poor,
with a 33% overall mortality rate (half of which was due
to febrile neutropenia) on day 30. In comparison with
other studies, the mortality rate was high but may be
explained by the fact that our study population was par-
ticularly severely affected: 60% had metastases and 31%
were non-operable [14,16].
Surprisingly, most of the identified bacteria were
germs of the urinary and digestive tracts (rather than
respiratory germs) and were predominantly detected by
blood culture. In contrast, the clinically documented
infections were mostly due to respiratory germs (53%,
vs. 23% for digestive tract infections). These findings
suggest that respiratory germs rarely cause bacteremia.
Fifteen percent of the infections were multidrug-resis-
tant and only 14% were hospital-acquired infections;
these are low values for a population which is frequently
hospitalized. However, multidrug-resistance and hospi-
tal-acquired infection did not appear to have a signifi-
cant impact on the overall failure rate antibiotic
treatment in our multivariate analysis, which identified
only age >60 and thrombocytopenia < 20000/mm
3 as
factors. The presence of thrombocytopenia as a risk fac-
tor for treatment failure probably reflects the hemotoxi-
city of chemotherapy. As expected, a univariate analysis
revealed that inappropriate antibiotic treatment was a
risk factor for first-line treatment failure. However, the
relatively low frequency of inappropriate treatment in
our study (14% of all patients and 36.4% of the cases of
microbiologically documented fever) did not prompt us
to change our guidelines on antimicrobial treatment.
Our guidelines did not include anti-pseudomonal peni-
cillin or cabapenem contrary as Hughes et al. propose
for high risk patients [7]. However our patients were on
the border between low and high risk patients. Accord-
ing to the same criteria, our patients had mostly those 4
following criteria for low risk patient: duration of neu-
tropenia less than 7 days, resolution of neutropenia
expected in <10 days, no neurological or mental
changes, no appearance of illness (40%); in addition,
according to the scoring index, most of our patients are
in the 20-22 points range. In a very similar population,
Rikimaru et al. observed that febrile neutropenia
occurred more frequently in patients with poor perfor-
mance status [17].
Table 4 Predictive factors of first-line antibiotic
treatment failure
Failure
n=2 4
n (%)
Success
n=6 3
n (%)
p
value
Mean age (years) 69.2 62.33 <0.001
Age >60 years 20 (83.3) 32 (50.8) 0.007
WHO Score ≥22 0 (83.3) 34 (54) 0.024
No. of comorbidities>2 4 (16.7) 7 (11.1) 0.487
Diabetes 7 (29.2) 10 (15.9) 0.225
Corticosteroid treatment 9 (37.5) 15 (23.8) 0.283
Pulmonary antecedents 15 (62.5) 43 (68.3) 0.800
COPD 14 (58.3) 32 (50.8) 0.470
Severe COPD
(FEV1<30% theory)
1 (4.2) 2 (3.2) 1
Small cell cancer 6 (25) 17 (27) 1
More than 1 chemotherapy 4 (16.7) 10 (15.9) 1
Metastases 18 (75) 36 (57.1) 0.145
Radiotherapy associated 6 (25) 19 (30.2) 0.793
G-CSF preventive 4 (16.7) 13 (20.6) 0.771
G-CSF curative 12 (50) 19 (30.2) 0.132
Already hospitalized patient 7 (29.2) 5 (7.9) 0.017
Altered general status 17 (70.8) 30 (47.6) 0.059
Dehydration 14 (58.3) 20 (31.7) 0.029
Gravity signs at admission 15 (62.5) 29 (46) 0.231
Delayed treatment 6 (25) 12 (19) 0.562
Neutropenia > 8 days 3 (12.5) 6 (9.5) 0.702
Neutrophils count <100/mm3 7 (29.2) 13 (20.6) 0.354
Haemoglobin <8 g/dl 9 (37.5) 32 (50.8) 0.465
Platelets < 20000/mm3 10 (41.7) 8 (12.7) 0.006
Decreasing of CRP 8 (33.3) 32 (50.8) 0.002
Undetermined origin of fever 6 (25) 34 (54) 0.018
Clinically documented fever (without
microbiological documentation)
6 (25) 8 (12.7) 0.196
Microbiologically documented fever 12 (50) 21 (33.3) 0.216
Respiratory signs 6 (25) 15 (23.8) 0.203
Bacteraemia 9 (37.5) 11 (17.5) 0.277
Gram negative bacilli 10 (41.7) 9 (14.2) 0.03
Multidrug resistant bacteria in patient
with at least one strain documented
4 (33.3) 2 (9.5) 0.159
Antibiotic treatment in last 6 month 6 (25) 16 (25.8) 1
Out patient first antibiotic treatment 4 (16.7) 10 (15.9) 1
Appropriateness between microbiology
and antibiotherapy in patient with at
least one strain documented
7 (58.3) 21 (100) 0.003
COPD = Chronic Obstructive Pulmonary Disease, CRP = C-reactive protein,
FEV1 = Forced Expiratory Volume in first second, G-CSF = Granulocyte colony-
stimulating factor, No = number.
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the data were non-exhaustive because of the exclusion
of non-hospitalized patients. However, the proportion of
cases with febrile neutropenia in our study (13%) is the
same as that found by Cullen et al. in a prospective, UK
study of patients with solid tumors (cancers and lym-
phoma). It may be that hospitalization of this type of
patient is more frequent in France than in the UK. Sec-
ondly, bacteriological samples (especially urine and spu-
tum samples) could have been contaminated and the
pathogenic classification of any isolated germs was left
to the attending physician in each case. Hence, there
may have been confusion bias. Thirdly, this was a retro-
spective study, with all the weaknesses associated with
this type of study design. However, in order to limit
selection bias, we selected all consecutive hospitalized
lung cancer patients and then excluded those lacking
fever and neutropenia. Some patients may have been
misclassified. Hence, all medical records charts were
carefully reviewed by one of the authors (E.P.) according
to pre-established criteria and were classified indepen-
dently of the initially reported laboratory results.
The febrile neutropenia mortality rate observed here
(16%) is greater than the value reported in a similar
study (3%). This disparity may be due to the severity of
our patients’ disease.
As mentioned above, our results revealed a greater
proportion of cases with fever of undetermined origin
(46%) than those with microbiologically documented
fever (38%) and clinically documented fever (16%). How-
ever, this difference has been found in other popula-
tions. Furthermore, fever of undetermined origin has a
better prognosis [14,18,19].
In the present study, microbiologically documented
fever was more likely to involve Gram-negative bacteria
than Gram-positive bacteria. Furthermore, Gram-
negative infections had a worse prognosis for antibiotic
treatment than Gram-positive infections did. In contrast
to our present results, Cordonnier et al. reported that
Gram-positive cocci were predominant. However, a few
studies in lung cancer patients have yielded similarly
discordant results: Markman and Berghams mainly
found Gram-negative bacteria, whereas Matsui and Niho
mainly found Gram-positive bacteria [11-13,20]. How-
ever, the study populations were somewhat different
(Table 5). These disparities do not appear to be time-
related (as Oppenheim has suggested for hematologic
patients). The high proportion of Gram-negative bac-
teria could be explained by the absence of aracytin use
and antifungal/antimicrobial decontamination (known to
facilitate Gram-positive bacterial infections). Further-
more, only three infections were related to a central
intravenous catheter (used in 92% of patients), which
are known to be primarily due to Gram-positive bac-
teria. In view of these differences, the results of the
above-mentioned studies should be interpreted with a
degree of caution and should probably not be general-
ized to other centers (at least not without knowing
more about the microbiological results in each center)
but could be extended to lung cancer patients.
Klastersky et al. reported on a huge cohort of 2142
patients with febrile neutropenia, of whom 164 had lung
cancer [16]. The aim of the latter study was to compare
the severity of disease in bacteremic and non-bacteremic
patients. The mortality rate was 8% in the small sub-
group of lung cancer patients and the data were not
analyzed further.
Kern reported that 20% of the infections were multi-
drug-resistant (versus 14.6% in the present study), with
an antibiotic treatment failure rate of 22% (versus 18.2%
here) [14]. The mortality rate due to infection was 2.5%
(versus 16% here) and the overall mortality rate at day
Table 5 Characteristics of infections in patients with lung cancer: review
Authors Population Patients
(n)
Fever
(n)
MDF
(%)
Gram -
(%
MDF)
Bacteria Gram+
(%
MDF)
Bacteria
Markman et
al.
11
1983
Small cell cancer neutropenic 72 126 11 61 E. coli
P. aeruginosa
31 S. viridans
S. aureus Bacillus
spp
Matsui et al.
12
1991
All lung cancer
Leukocytes count <3000/mm3
- 101 58 44 - 56 -
Berghmans et
al.
20
2003
All lung cancer neutropenic and non
neutropenic
275 435 60 64 H. influenzae
M. catarrhalis
E. coli
P. aeruginosa
25 S. pneumoniae
S. aureus
Niho et al.
13
2004
All lung cancer neutropenic 35 41 12 40 P. aeruginosa
H. influenzae
60 S. pneumoniae
S. aureus
Enterococcus
Lanoix et al.
2011
All lung cancer neutropenic 87 87 38 58 E. coli
other
Enterobacteriaceae
40 S. aureus
S. epidermidis
MDF: microbiologically documented fever.
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population differed from ours and was considered to be
at low risk of infection.
Conclusion
The present study emphasized two important points.
Firstly, the microbiological profile of febrile neutropenia
does not differ greatly from that seen in other types of
neutropenia. Respiratory germs are less predominant
than S. aureus and enterobacteriaceae and lung infection
is not a prognostic factor (since only age and perfor-
mance status were predictive of antibiotic treatment fail-
ure). Secondly, our results highlight the progression of
the infection; the higher mortality rate was due more to
the patients’ fragility than the nature of the germs or
the presence of multidrug resistance. Extremely broad-
spectrum antibiotic therapy is not always necessary but
treatment must take account of the patient’s frailty and
the presence of respiratory germs.
In order to circumvent the limitations of retrospective
studies and avoid selection bias, it would be useful to
perform the same type of study on a prospective basis
and include non-hospitalized patients.
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